About HKTDC | Media Room | Contact HKTDC | Wish List Wish List () | My HKTDC |
繁體 简体
Save As PDF Print this page
Qzone

China Adopts Reformatted Drug Manufacturing Permits from 1 September

China has reformatted its drug manufacturing permits and associated documentation in a bid to unify the look and content of its administrative licences. One of the most notable changes is the enhanced prominence of contact numbers for the day-to-day supervisory body and the relevant complaints hotline, a move designed to improve oversight and boost consumer confidence.

The new permits will be issued by the relevant provincial (regional and municipal) medical products administrative bodies from 1 September this year, with both the printed and digital versions conforming to the same template. In the case of permits expiring after 31 December, these will be replaced by reformatted documents before the end of next year, with their validity period remaining unchanged.

Full details of these reformatted permits can be found in the Circular on Putting into Use the New-Format Drug Manufacturing Permit and Other Permits (Yao Jian Zong Yao Guan No. 72 [2019]), as issued by the National Medical Products Administration on 25 July 2019.

Source: National Medical Products Administration

Content provided by Picture: HKTDC Research
Comments (0)
Shows local time in Hong Kong (GMT+8 hours)

HKTDC welcomes your views. Please stay on topic and be respectful of other readers.
Review our Comment Policy

*Add a comment (up to 5,000 characters)